Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering

The programmed cell death protein 1 (PD-1) signaling pathway is a major source of dampened T cell activity in the tumor microenvironment. While clinical approaches to inhibiting the PD-1 pathway using antibody blockade have been broadly successful, these approaches lead to widespread PD-1 suppression, increasing the risk of autoimmune reactions. This study reports the development of an ionizable lipid nanoparticle (LNP) platform for simultaneous therapeutic gene expression and RNA interference (RNAi)-mediated transient gene knockdown in T cells. In developing this platform, interesting interactions are observed between the two RNA cargoes when co-encapsulated, leading to improved expression and knockdown characteristics compared to delivering either cargo alone. This messenger RNA (mRNA)/small interfering RNA (siRNA) co-delivery platform is adopted to deliver chimeric antigen receptor (CAR) mRNA and siRNA targeting PD-1 to primary human T cells ex vivo and strong CAR expression and PD-1 knockdown are observed without apparent changes to overall T cell activation state. This delivery platform shows great promise for transient immune gene modulation for a number of immunoengineering applications, including the development of improved cancer immunotherapies.

Automated summary

A ionizable lipid nanoparticle (LNP) platform was developed for simultaneous therapeutic gene expression and RNA interference (RNAi)-mediated transient gene knockdown in T cells. Co-encapsulating mRNA and siRNA resulted in improved expression and knockdown characteristics compared to delivering either cargo alone. This platform was used to deliver CAR mRNA and siRNA targeting PD-1 to primary human T cells ex vivo, leading to strong CAR expression and PD-1 knockdown without apparent changes to overall T cell activation state. This delivery platform shows great promise for transient immune gene modulation in immunoengineering applications, including improved cancer immunotherapies.